MMI Co-Founder, John Hipp, PhD. selected as Guest Editor for Special Issue of Bioengineering!
Although the trial process shows strong signs of continued improvement, choosing the right clinical research partner remains crucial to success.
The U.S. Food and Drug Administration (FDA) has approved Q.Clear, a new development by GE Healthcare that the company claims will improve accuracy and quality in PET/CT imaging
Medical Metrics, Inc. (MMI), a leading provider of imaging core lab services for orthopedic clinical trials, has been selected by five leading orthopedic device manufacturers to support multiple cross-sectional, post-market, FDA surveillance studies of metal-on-metal (MoM) hip implants. MMI will independently evaluate radiographs and MRI to assess long-term outcomes in patients implanted with MoM hips. …
MMI’s scientific staff and physician consultants specialize in joint replacement studies and the current client list includes global leaders in joint arthroplasty.
Medical Metrics, Inc. (MMI), an experienced provider of medical imaging core lab services for global clinical trials, has been selected by Exactech, Inc. to conduct an independent evaluation of medical images from the BiPhasic Cartilage Repair Implant (BiCRI) IDE Clinical Trial approved by the Taiwan FDA. This prospective, randomized study will be conducted in Taiwan to …
Medical Metrics, Inc. (MMI) announces that it has successfully achieved ISO 9001:2008 certification of its Quality Management System in support of imaging core lab services for orthopedic, spine, cardiovascular and neurological clinical trials.
QMA® continues to gain widespread acceptance in pre-clinical, clinical and research applications studying intervertebral motion as evidenced by the growing number of scientific publications.
